杭州浙大迪迅生物基因工程有限公司杭州浙大迪迅生物基因工程有限公司

0571-87968248 CHINESE
  • Home
  • About us
    ProfileCultureHistory
  • News
    Company newsTrade showsIndustry news
  • Products
    COVID-19 IgG/IgM Rapid Test KitAllergen-specific IgE antibodies test kit seriesFood-specific IgG/IgG4 antibodies test seriesSingle/Polynomial allergen test seriesSingle allergen component test seriesGenetic test for allergic diseases series productsOther seriesProduct specific equipment
  • About allergies
    Scientific literaturePopular scienceVideos
  • Contact us
    Join usContact us
Scientific literaturePopular scienceVideos
Components literatureGene literatureMechanism literatureProbioticsTest literatureDesensitizationOther

Release date：2018-12-24


JACI:
[IF:13.1]
Immunologic characterization of monoclonal antibodies that modulate human IgE binding to the major birch pollen allergen Bet v 1
https://doi.org/10.1016/S0091-6749(97)70056-3
Abstract:
Background
Background: Bet v 1 and homologous proteins represent major allergens for almost 95% of patients allergic to tree pollen and approximately 70% of those allergic to fruits and vegetables. As yet, no continuous (sequential) IgE epitopes have been determined for Bet v 1, and evidence has accumulated that Bet v 1 IgE epitopes belong to the conformational (discontinuous) type. Objective: A panel of 85 mouse monoclonal anti-Bet v 1 antibodies was raised as a tool with which to study the interaction of human IgE antibodies with Bet v 1. Methods: The epitopes of selected monoclonal antibodies (mAbs) were characterized by mapping with synthetic overlapping peptides and by cross-competition experiments. Cross-reactivity of Bet v 1–specific mAbs with tree and plant food allergens was investigated by Western blotting. The influence of Bet v 1–specific mAbs on the IgE–Bet v 1 interaction was studied by competition assays with immobilized purified recombinant Bet v 1 and by basophil histamine release experiments. Results: Antibodies that increased the IgE binding to Bet v 1 up to fivefold could be defined, whereas others inhibited IgE binding to Bet v 1 up to 99% and competed with the Bet v 1–induced histamine release from patients' basophils. Conclusion: The activity of the enhancing antibodies is interpreted as a stabilization of Bet v 1 states/IgE epitopes, which are either more accessible for certain IgE antibodies or are recognized with higher affinity. Those mAbs that competed with the Bet v 1–IgE interaction, if humanized or produced as recombinant antibody fragments, might be considered as potential tools for local allergy therapy. (J Allergy Clin Immunol 1997;99:374-84.)
All Author:
Serge Lebecque, MDa, Christiane Dolecek, MDb, Sylvia Lafferb, Vincenzo Visco, PhDa, Stéphanie Denépouxa, Jean-Jacques Pina, Christiane Gureta, George Boltz-Nitulescu, PhDb, Anne Weyer, PhDc, Rudolf Valenta, MDb
2018-12-21  Article
  • Home
  • About us
  • News
  • Products
  • About allergies
  • Contact us
Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd.  Copyright    HZKC Technical support   浙ICP备14005341号   （浙）-非经营性-2019-0050
Address: Rm.201-209, Bldg.2, No.568 Binkang Rd., Binjiang Dist.      Tel: 0571-87968248-805     Website:www.zdbiogene.com

COPYRIGHT©2003-2024 www.zdbiogene.com CORPORATION. ALL RIGHTS RESERVED

Official WeChat